Cytogenomic Molecular Inversion Probe Array, FFPE Tissue - Oncology
Ordering Recommendation
Preferred test for FFPE tissue at time of diagnosis for detecting prognostically important genomic abnormalities in leukemias/lymphomas and solid tumors involving
Loss/gain of DNA
Loss of heterozygosity (LOH)
Monitor disease progression and response to therapy.
Molecular Inversion Probe Array
2-3 weeks
New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
Submit With Order
Specimen Required
Patient Preparation
Tumor tissue  
Specimen Preparation
Formalin fix (10 percent neutral buffered formalin) and paraffin embed tissue. Protect from excessive heat. Transport 10 slides, each with 5-micron unstained sections or four 20-micron scrolls or tissue block. Tissue block will be returned after testing. Transport tissue in a tissue transport kit (ARUP supply #47808) available online through eSupply using ARUP Connect or contact ARUP Client Services at (800) 522-2787.  
Storage/Transport Temperature
Room temperature. Also acceptable: Refrigerated. Ship in cooled container during summer months.  
Unacceptable Conditions
Specimens fixed or processed in alternative fixatives or heavy metal fixatives (B-4 or B-5).  
Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable  
Reference Interval
Interpretive Data
For detection of copy number alterations and loss of heterozygosity in FFPE specimens.
Refer to report.

Compliance Statement C: The performance characteristics of this test were validated by ARUP Laboratories. The U.S. Food and Drug Administration (FDA) has not approved or cleared this test; however, FDA approval or clearance is currently not required for clinical use of this test. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. ARUP is authorized under Clinical Laboratory Improvement Amendments (CLIA) and by all states to perform high-complexity testing.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.
Samples must contain a region with at least 50 percent tumor.
CPT Code(s)
88381; 81406
Component Test Code*Component Chart NameLOINC
2010230Cytogenomic MIP Array, FFPE62375-1
2010231EER Cytogenomic MIP Microarray, FFPE11526-1
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • aCGH
  • array CGH
  • Array Comparative Genomic Hybridization
  • CGH
  • Chromosomal Microarray
  • CMA
  • Microarray
  • oncology, formalin-fixed, paraffin-embedded, FFPE
  • Single-nucleotide-polymorphism (SNP) array
  • tissue
  • tumor
  • Whole Genome Array